NOTCH1 and cancer: Previous work from our group and Dr. Stegmaier’s laboratory identified the Sarco-endoplasmic Ca2+-ATPase (SERCA) as a potential therapeutic target in NOTCH1-mutated cancers, overcoming the innate limitations associated with GSI [11] that equally target WT and mutated NOTCH1 proteins [11,12].